Thiazolides: A new class of drugs for the treatment of chronic hepatitis B and C

Future Microbiology

Volumn 3, Issue 5, 2008, Pages 539-545

  Rossignol, Jean François ^a,b   Keeffe, Emmet B ^a,b,c  

^a Romark Institute for Medical Research   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Romark Laboratories LC   (United States)

Author keywords

Chronic hepatitis B; Chronic hepatitis C; Eukaryotic initiation factor 2 phosphorylation; HBV; HCV; Interferon; Nitazoxanide; Peginterferon; Protein kinase RNA activated phosphorylation; Ribavirin; Thiazolides

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; LAMIVUDINE; NITAZOXANIDE; PEGINTERFERON ALPHA2A; RIBAVIRIN; RM 4863; THIAZOLIDINE DERIVATIVE; TIZOXANIDE; UNCLASSIFIED DRUG; THIAZOLE DERIVATIVE;

ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; HEPATITIS B; HEPATITIS C; HUMAN; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; RETREATMENT; REVIEW; SEROCONVERSION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

CRYPTOSPORIDIUM PARVUM; EUKARYOTA; HEPATITIS B VIRUS; HEPATITIS C VIRUS;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; THIAZOLES;

EID: 55449122030     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.3.5.539     Document Type: Review

References (34)

1. Anderson VR, Curran MP: Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 67, 1947-1967 (2007).
2. Aslam S, Musher DM: Nitazoxanide: clinical studies of a broad-spectrum anti-infective agent. Future Microbiol. 2. 583-590 (2007).
3. Fox LM, Saravolatz LD: Nitazoxanide: a new thiazolide antiparasitic agent. Clin. Infect. Dis. 40, 1173-1180 (2005).
4. White AC Jr: Nitazoxanide: a new broad spectrum antiparasitic agent. Expert. Rev. Anti-infect. Ther. 2, 43-50 (2004).
5. Rossignol JF, Cavier R: New derivative of 2-benzamido 5-nitrothiazoles. Chem. Abstr. 83, 28216n (1975).
6. Euzéby J, Prom Tep S, Rossignol JF: Expérimentation des propriétés anthelminthiques de la nitazoxanide chez le chien, le chat et les ovins. Revue de Médecine Vétérinaire 131, 687-696 (1980).
7. Cavier R, Rossignol JF: Etude pharmacologique de diverses associations d'anthelminthiques chez la souris. Revue de Médecine Vétérinaire 133, 779-783 (1982).
8. Rossignol JF, Maisonneuve H: Nitazoxanide in the treatment of Taenia saginata and Hymenolepis nana. Am. J. Trop. Med. Hyg. 33, 511-512 (1984).
9. Rossignol JF, Ayoub A, Ayers MS: Treatment of diarrhea caused by Cryptosporidium parvum: a propective randomized double-blind placebo-controlled study of nitazoxanide. J Infect. Dis. 184, 103-106 (2001).
10. Amadi B, Mwiya M, Musuku J et al.: Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 360, 1375-1380 (2002).
11. Rossignol JF, Kabil SM, Younis A M, El-Gohary Y: Double-blind placebo controlled study of nitazoxanide in the treatment of cryptosporidial diarrhea in 90 immunocompetent adults and adolescents from the Nile delta of Egypt. Clin. Gastroenterol. Hepatol. 4, 320-324 (2006).
12. Rossignol JF, Hidalgo H, Feregrino M et al.: A double-blind placebo controlled study of nitazoxanide in the treatment of cryptosporidial diarrhea in AIDS patients. Trans. R. Soc. Trop. Med. Hyg. 92, 663-666 (1998).
13. Dubreuil L, Houcke I, Mouton Y, Rossignol JF: In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob. Agents Chemother. 40, 2266-2270 (1996).
14. McVay CS, Rolfe RD: In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob. Agents Chemother. 44. 2254-2258 (2000).
15. Pankuch GA, Appelbaum PC: Activities of tizoxanide and nitazoxanide compared to those of five other thiazolides and three other agents against anaerobic species. Antimicrob. Agents Chemother. 50, 1112-1117 (2006).
16. Hech DW, Galang MA, Sambol SP, Osmolski JR, Johnson S, Gerding DN: In vitro activities of 15 antimicrobial agents against 110 toxogenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob. Agents Chemother. 51, 2716-1719 (2007).
17. Musher DM, Logan N, Hamill RJ et al.: Nitazoxanide in the treatment of Clostridium difficile associated diseases. Clin. Infect. Dis. 43, 421-427 (2006).
18. Musher DM, Logan ND, Bressler AM, Johnson DP, Rossignol JF: Nitazoxanide in the treatment of Clostridium difficile disease [abstract]. Gastroenterology 134(Suppl. 1), A-669 (2008).
19. Hoffman PS, Sission G, Croxen MA et al.: Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites and Campilobacter jejuni. Antimicrob. Agents Chemother. 51, 868-876 (2007).
20. Stockis A, Allemon AM, De Bryn S, Gengler C: Nitazoxanide pharmacokinetics and tolerability in man after single ascending oral doses, Int. J. Clin. Pharmacol. 40, 213-220 (2002).
21. Stockis A, Allemon AM, Gengler C, Rosillon D: Nitazoxanide pharmacokinetics and tolerability in man during 7 days of 0.5 g and 1 g b.i.d. dosing. Int. J. Clin. Pharmacol. 40, 221-227 (2002).
22. Stockis A, Deroubaix X, Lins R et al.: Pharmacokinetics of nitazoxanide after single oral dose administration in 6 health volunteers, Int. J. Pharmacol. Ther. 34, 349-351 (1996).
23. Broekhuysen J, Stockis A, Lins RL, De Graeve J, Rossignol JF: Nitazoxanide: pharmacokinetics and metabolism in man. Int. J. Clin. Pharmacol. Ther. 38, 387-394 (2000).
24. Matysiak-Budnik T, Mégraud F, Heyman M: In vitro transfer of nitazoxanide across the intestinal barrier. J. Pharm. Pharmacol. 54, 1413-1417 (2002).
25. Vets E, Rossignol JF, Jackson AS: Nitazoxanide co-administration with warfarin sodium: a Phase I crossover study. Am. J. Health Syst. Pharm. (2008) (In press).
26. Korba BE, Montero AB, Farrar K et al.: Nitazoxanide, tizoxanide, and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication. Antivir. Res. 77, 56-63 (2008).
27. Korba BE, Elazar M, Lui P et al.: Studies of the potential for nitazoxanide or tizoxanide resistance in hepatitis C virus replicon-containing cell lines. Antimicrob. Agents Chemother. (2008) (In press).
28. Kolozsi WZ, El-Gohary Y, Keeffe EB, Rossignol JF: Treatment of chronic hepatitis B (CHB) with nitazoxanide (NTZ) alone or NTZ plus adefovir (ADV) for two years with loss of hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg): report of two cases [abstract]. Am. J. Gastroenterol. (2008) (In press).
29. Rossignol JF, Kabil SM, El-Gohary Y, Elfert A, Keeffe EB: Clinical trial: randomized, double-blind, placebo-controlled study of nitazoxanide monotherapy for the treatment of patients with chronic hepatitis C genotype 4. Aliment. Pharmacol. Ther. 28, 574-580 (2008).
30. Rossignol JF, Elfert A, El-Gohary Y, Keeffe EB, Glenn JS: Interim data from a randomized controlled trial of nitazoxanide-peginterferon-ribavirin, nitazoxanide-peginterferon and peginterferon-ribavirin in the treatment of patients with chronic hepatitis C genotype 4 [abstract]. Hepatology 46(Suppl. 1), 316A-317A (2007).
31. Rossignol JF, Elfert A, El-Gohary Y. Keeffe EB: Randomized controlled trial of nitazoxanide-peginterferon-ribavirin, nitazoxanide-peginterferon and peginterferon-ribavirin in the treatment of patients with chronic hepatitis C genotype 4 [abstract]. J. Hepatol. 48(Suppl. 2), S30 (2008).
32. Rossignol JF, Elfert A, Keeffe EB: Evaluation of a 4 week lead-in phase with nitazoxanide prior to nitazoxanide + peginterferon in treating chronic hepatitis C [abstractl. J. Hepatol. 48(Suppl. 2), S312 (2008).
33. Rossignol JF, Elfert A, Keeffe EB: Evaluation of a 4 week lead-in phase with nitazoxanide (NTZ) prior to peginterferon (PegIFN) plus NTZ for treatment of chronic hepatitis C: final report. Hepatology (2008) (In press).
34. Elazar M, Liu M, McKenna S et al.: Nitazoxanide (NTZ) is an induced of eIF2α and PKR phosphorylation [abstractl. Hepatology (2008) (In Press).